A groundbreaking surgical therapy capable of stabilising and restoring vision in the vast majority of patients who currently suffer blindness through Age-Related Macular Degeneration (AMD) is to be taken to clinical trial by scientists and clinicians at the UCL Institute of Ophthalmology, Moorfields Eye Hospital and the University of Sheffield. The therapy, using cells derived from human embryonic stem cells to replace the faulty retinal cells that cause AMD, will be developed by the London Project to Cure AMD, a collaborative project launched today bringing together some of the leading specialists in the field.
Around 25 per cent of over-60s in the UK have some degree of visual loss due to AMD, and some 14 million people in Europe currently suffer blindness through the condition, caused by defects in the retinal support cells. There is currently no treatment that prevents the treatment of dry AMD. There has been some success in controlling new blood vessel formation in wet AMD, but these approaches are only suitable for certain patients and are often only temporary.
Thanks to a £4 million donation from a US private donor, the London Project will now be able to assemble the necessary spectrum of scientists and clinicians, led by the UCL Institute of Ophthalmology, to accelerate the technique's move from laboratory to clinic. The Project is open access and will be made completely available to scientists, clinicians and all those with an interest worldwide.
AMD is associated with defects of the retinal support cells -- the retinal pigment epithelial cells (RPE). The rods and cones (the photoreceptors) in the retina, which are the light sensitive cells, depend for their survival on the normal functioning of these cells, and so failure of these cells leads to progressive loss of vision. In addition, the disease often provokes a scarring process at the back of the eye leading to the formation of new blood vessels within the retina which subsequently leak fluid resulting in exudative or so called "wet" AMD.
The London Project's approach will involve production of a cell replacement therapy from human embryonic stem cells, which are effective in replacing dysfunctional RPE and photoreceptors found in AMD, leading to a surgical therapy capable of stabilising and restoring vision in the vast majority of patients. Surgical procedures already developed and trialled in a number of patients using the patients' own cells have illustrated that a cell replacement therapy can work.
Professor Pete Coffey, UCL Institute of Ophthalmology and director on the London Project, said: "The London Project aims to deliver treatment for a disease which has no alternative therapy. Using stem cells -- which are far more adaptable -- can only improve success of what has already been achieved and in addition establish this as a global therapy. This is achievable as a result of bringing together a number of groups who previously were trying to solve the same problem in isolation. The Project aims to engage scientists, clinicians and the public to ensure success through actively attracting and promoting the inclusion of other laboratories, hospitals and institutions by an open access policy and by informing the public of progress."
Dr Lyndon Da Cruz, lead clinician and consultant ophthalmic surgeon, Moorfields Eye Hospital, said: "The Project is important as it develops a cellular based therapy for a currently untreatable condition. The beauty of this Project is that there are three specialist groups working in parallel; a team in Sheffield, the UCL Institute of Ophthalmology and Moorfields Eye Hospital. Working in conjunction, they will be respectively safety testing the cells in Sheffield, confirming that the cells are RPE cells and preparing them in a form for transplant at the Institute of Ophthalmology, and developing the strategies for the surgery and patient selection based on studies on transplanting autologous RPE (i.e. cells from the patients' own eyes) at Moorfields.
"By driving these in parallel it is felt that the development time will be significantly reduced. Given that AMD could affect up to one third of the population by 2070, and that the bulk of these will have dry AMD, the potential to create a treatment strategy for this condition is critical and may have a major impact on vision loss in the community."
Professor Ed Byrne, Dean of the UCL Faculty of Biomedical Sciences, said: "The launch of The London Project to Cure AMD reinforces UCL's position at the forefront of stem cell research in the UK and beyond. We hope that like-minded individuals and organisations will continue to donate funds to world-class research projects such as this, which have the capability of developing life-changing treatments for diseases such as AMD."
Professor Alistair Fielder, Senior Medical Adviser of Fight for Sight, the leading eye research charity, said: "We are excited about the work of Professor Pete Coffey and his team regarding developments in the treatment of AMD. The London Project represents a real chance to tackle this untreatable condition and bring hope to many. It is marvellous to think that clinical trials could start within five years."
Tom Bremridge, Chief Executive of The Macular Disease Society, said: "This development is exciting and encouraging for current and future generations of AMD patients. While treatments for 'wet AMD' are advancing rapidly, sadly patients with 'dry AMD' have had no prospect of any viable therapy. Our thanks and congratulations to the instigators of the London Project to Cure AMD."
Materials provided by University College London. Note: Content may be edited for style and length.
Cite This Page: